We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Opko Health Inc | NASDAQ:OPK | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.02 | -1.54% | 1.28 | 1.27 | 1.28 | 1.35 | 1.29 | 1.32 | 4,487,673 | 00:55:06 |
From May 2019 to May 2024
By Colin Kellaher
Pfizer Inc. and OPKO Health Inc. on Monday said the U.S. Food and Drug Administration accepted for review their application for somatrogon, a once-weekly human-growth hormone for pediatric patients with growth-hormone deficiency.
The companies said the agency set a target action date in October for somatrogon, which, if approved, would help reduce the burden of daily growth-hormone injections.
New York drug maker Pfizer and OPKO, a Miami healthcare-services company, signed a worldwide agreement in 2014 to develop and commercialize somatrogon for growth-hormone deficiency.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 04, 2021 08:54 ET (13:54 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Opko Health Chart |
1 Month Opko Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
